Linical Co., Ltd. Revises Earnings & Dividend — Net Profit Down 39.8%
Linical Co., Ltd. (TSE:21830) has revised its earnings and dividend forecast for the full fiscal year ending March 31, 2026, citing weaker-than-expected performance in key markets.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 9.35bn | JPY 8.66bn | △JPY 0.69bn (△7.3%) |
| Operating Profit | JPY -1.35bn | JPY -2.14bn | △JPY 0.79bn (＋62.1%) |
| Ordinary Income | JPY -1.40bn | JPY -2.10bn | △JPY 0.70bn (＋49.9%) |
| Net Profit | JPY -1.70bn | JPY -2.38bn | △JPY 0.68bn (＋39.8%) |
| EPS | JPY -75.27 per share | JPY -105.24 per share | △JPY 30.00 per share (＋40.0%) |
| Annual Dividend | JPY 16.00 per share | JPY 8.00 per share | △JPY 8.00 per share (△50.0%) |
The company attributed the downward revision to delayed project wins in Japan and postponed large-scale international clinical trials in the U.S., Europe, and Australia. These factors are expected to weigh on results during the second half of the fiscal year.
The revision signals management's acknowledgment of underperformance and highlights ongoing challenges in key markets. While the company has not provided specific guidance on future earnings recovery, it has stated its commitment to improving performance through strategic initiatives. Investors should monitor progress on these efforts and potential shifts in market conditions.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.